or Try an Advanced Search...

    Technical Analysis for ENTO - Entero Therapeutics Inc.

    Grade Last Price % Change Price Change
    C 0.69 7.50% 0.05
    ENTO closed up 7.5 percent on Friday, November 1, 2024, on 27 percent of normal volume.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical ENTO trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Narrow Range Bar Range Contraction 7.50%
    Wide Bands Range Expansion 7.50%
    Up 3 Days in a Row Strength 7.50%
    1,2,3 Pullback Bullish Bullish Swing Setup 12.82%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 12.82%
    NR7 Range Contraction 12.82%
    Narrow Range Bar Range Contraction 12.82%
    Older End-of-Day Signals for ENTO ...

       Recent Intraday Alerts

    Alert Time
    Up 10% 1 day ago
    60 Minute Opening Range Breakout 1 day ago
    Rose Above Previous Day's High 1 day ago
    Up 5% 1 day ago
    Up 3% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ENTO Chart by TradingView
    Basic chart:

    Profile

    Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19

    Is ENTO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 16 Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
    Sep 10 Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
    Aug 23 Entero Therapeutics receives Nasdaq notification regarding delayed form 10-Q
    Aug 23 Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
    Jul 31 Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
    Jul 26 Entero Therapeutics files secondary offering of 3.5M shares
    Jul 11 Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
    Jul 9 Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium
    Jun 27 Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
    May 22 Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
    See more ENTO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.5
    52 Week Low 0.1873
    Average Volume 429,187
    200-Day Moving Average 2.44
    50-Day Moving Average 0.46
    20-Day Moving Average 0.57
    10-Day Moving Average 0.63
    Average True Range 0.09
    RSI (14) 61.39
    ADX 40.24
    +DI 37.22
    -DI 13.98
    Chandelier Exit (Long, 3 ATRs) 0.58
    Chandelier Exit (Short, 3 ATRs) 0.63
    Upper Bollinger Bands 0.78
    Lower Bollinger Band 0.37
    Percent B (%b) 0.77
    BandWidth 72.92
    MACD Line 0.06
    MACD Signal Line 0.05
    MACD Histogram 0.0025
    Fundamentals Value
    Market Cap 1.07 Million
    Num Shares 1.56 Million
    EPS 1131.40
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 2.56
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.79
    Resistance 3 (R3) 0.79 0.76 0.78
    Resistance 2 (R2) 0.76 0.73 0.76 0.77
    Resistance 1 (R1) 0.72 0.71 0.74 0.72 0.76
    Pivot Point 0.69 0.69 0.69 0.69 0.69
    Support 1 (S1) 0.65 0.66 0.67 0.65 0.61
    Support 2 (S2) 0.62 0.64 0.62 0.61
    Support 3 (S3) 0.58 0.62 0.60
    Support 4 (S4) 0.58